Skip to main content
. Author manuscript; available in PMC: 2023 Dec 8.
Published in final edited form as: Cancer Immunol Immunother. 2023 Oct 17;72(12):3985–3999. doi: 10.1007/s00262-023-03530-3

Figure 2.

Figure 2.

Expression of PD-L1 in mouse MC-38 colon cancer cells and regulation by NR4A1. MC-38 cells were transfected with oligonucleotides targeting NR4A1 and PD-L1 (A), Sp1 or treated with mithramycin (B) or treated with DIM-3-Br-5-OCF3 and DIM-3,5-Cl2 (C) or stable MC-38 NR4A1 KO cells generated by CRISPR/Cas9 and two clones (Clone 7 and Clone 14) (D) and whole cell lysates were analyzed by western blots. E. Model of the GC-rich mouse PD-L1 promoter and primers targeting this region for the ChIP assay. MC-38 cells were treated with DMSO 7.5 μM DIM-3-Br-5-OCF3 and 7.5 μM DIM-3,5-Cl2 and interaction on the GC-rich PD-L1 gene promoter were determined in a ChIP assay. F. Model of the GC-rich human PD-L1 promoter and primers targeting this region in the ChIP assay; SW480 and RKO cells were treated as described and interactions with the PD-L1 promoter were determined in a ChIP assay as outlined in the Methods. Figures were created partly with BioRender (https://app.biorender.com)